Theranos Whistleblower Warns the AI Boom Makes Deception Easier

The man who helped expose Theranos is telling investors something they do not want to hear: the AI boom is a better machine for deception than Theranos ever was. Tyler Shultz watched a company reach a roughly $10 billion valuation on blood-testing devices that did not work. Now he says AI claims are even harder to check — and the money is moving faster, at far larger scale, on far less proof.

That is not a warning about one bad actor. It is a warning about a system that keeps paying for the story and skipping the verification.

A demo is not evidence

Shultz's sharpest line cuts straight through the pitch-deck theatre: it is "really hard to tell the difference between what is something truly unique and new versus like, a ChatGPT wrapper." From the outside, a genuine breakthrough and a thin layer on someone else's model look identical — polished, confident, and demo-ready. A blood test either returns the right result or it does not. An AI product can look brilliant in a controlled demo and fall apart in real use, and nobody in the room may be able to tell the difference.

Secrecy is the oldest trick in the book

Theranos withheld scientific evidence from investors, citing trade secrets — and that secrecy kept the serious venture firms away while wealthy individuals wrote cheques they could not independently verify. Sound familiar? When an AI vendor hides how its model was evaluated, how often it fails, or what it actually does that the underlying model does not, that is not competitive discipline. That is asking you to trust instead of judge. Shultz's rule is blunt: the days of a thirty-minute coffee and a $100,000 cheque should be over. Holmes, he notes, scaled that model to $100 million.

Valuation is not validation

Theranos combined a $10 billion valuation with withheld evidence, and none of it made its devices work. The AI era is repeating the pattern at trillion-dollar scale, with companies that have never turned a profit raising capital on claims nobody has independently verified. Charisma, momentum, and a competitive round are signals to investigate — not proof. When verification feels costly because the round is moving fast, that is exactly when it needs to be a precondition, not an afterthought.

The second act should make you uneasy, not reassured

The documentary about Holmes's final weeks before prison has revived the conversation, and with it the news that a diagnostics company described as "Theranos 2.0" has reportedly raised about $20 million. Shultz's response — "I have this feeling of unease about what might come next" — is deliberately restrained: no commercial product, no independently validated data published, and a disputed departure by its former CTO. None of that proves wrongdoing. All of it proves why unease, and evidence, should come before money.

Ask these questions before you pay or deploy

• What was actually tested, on what data, with what failure rate — and who verified it independently? A demo is not an answer.
• What does this system do that the underlying model, used directly, does not? If the answer is a nicer interface and a pitch deck, you are looking at a wrapper.
• What was withheld as proprietary, and what does that leave you unable to check? Secrecy may be legitimate, but unverifiable claims are not diligence.
• What happens when it fails in conditions like yours? For buyers handling customer data, medical information, or financial decisions, demand reliability evidence and a human route back — before you rely on it for anything high-stakes.

Shultz is not claiming every AI company is a fraud, and high valuations alone prove nothing. His point is narrower and more damning: when claims cannot be checked, money and trust flow on the strength of the story. Theranos proved a closed, secretive, charismatic company could reach $10 billion on technology that did not work. AI makes that pattern easier to repeat, not harder — because deception no longer needs to be sophisticated. It only needs to be unverified.

Go deeper

Read the full article, including the complete due-diligence checklist for AI claims: Theranos Whistleblower Warns the AI Boom Makes Deception Easier

Originally published on Agentic Affairs (https://agentic-affairs.com)